Press Releases

CJ Biomaterials, Inc., a division of South Korea-based CJ CheilJedang and a primary producer of polyhydroxyalkanoate (PHA) biopolymers, has partnered with Dongsung Chemical to introduce the first PHA-based hotmelt adhesive available in the US market. Designed for packaging applications, the ECOVIVA® Hotmelt Adhesive is optimized for cosmetics packaging, household goods, electronics, and other consumer packaging, and it effectively bonds challenging substrates, including paper to aluminum

GC Cell, a leader in the cell and gene therapy (CGT) sector within the biopharmaceutical industry, and QuantHealth, the global leader in AI-powered clinical trial simulation, have announced a collaboration to bring a simulation-first approach to the design of upcoming clinical trials for GCC2005, GC Cell's investigational CD5-targeted CAR-NK cell therapy for T-cell lymphoma. The collaboration is intended to advance GCC2005's global clinical development strategy and enhance t

Baker Perkins, a leading supplier of nutraceutical and food processing equipment, announces the launch of the ServoForm™ Flexi+, an advanced, starch-free gummy manufacturing system, combining highly efficient depositing & demoulding technology with automated mould handling. Designed specifically for nutraceutical, functional product, and confectionery manufacturers, the ServoForm Flexi+ system delivers the automation of traditional starch

Thewaico, a bioprocess innovation company, today emerged from stealth with an integrated bioreactor and bioprocess control platform developed to address one of biomanufacturing's most persistent and costly failures: processes that perform reliably at laboratory scale but break down at production volumes, largely because the underlying software and hardware were never designed for a continuous path to scale. The economic cost is substantial. According to analyses by Boston Consul

Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today the signing of an exclusive distribution agreement with Kyowa Kirin International (“KKI”), a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151) (“Kyowa Kirin”), a Japan-based global specialty pharmaceutical company, for mogamulizumab (sold as POTELIGEO® in the United States and Europe) across certain Latin American countries. Under the t

World-changing experts at the University of Glasgow will partner with scientists at leading pharmaceutical company Eli Lilly and Company (Lilly) to tackle immune-related diseases. The £7.6m four-year project expands on an initial five-year collaboration focused on the discovery of potential new treatment options and therapies for patients living with a range of immune-related conditions. This expansion is testament to the depth of world-leading expertise in immunolog

Thermo Fisher Scientific, the world leader in serving science, today announced the Gibco™ CHO-K1 Catalog Panel, a cGMP-ready portfolio of basal and feed media designed to support strong cell growth and protein production across CHO-K1 cell lines. Available in liquid and dry powder media (DPM) formats, the panel can offer flexible options for process development, scale-up, and manufacturing. The panel consists of multiple basal media and feed combinations designed for a broad r

Envisagenics today announced a multi-year research collaboration and option agreement with Boehringer Ingelheim to validate selected tumor-specific targets for the development of first-in-class precision therapies for people living with solid tumors. Envisagenics has pioneered an artificial intelligence (AI)-powered approach that is transforming alternative RNA splicing into a new frontier for drug discovery. Despite significant advances in cancer treatment, progress has not reached

Switzerland based Tenthpin Management Consultants, a global leader in management and technology consulting for Life Sciences companies has announced the launch of Innovation Hub in Bengaluru, establishing a Global Centre of Excellence dedicated to advanced therapies that delivers a cutting-edge AI and cloud-driven solutions that help organizations accelerate and transform complex gene, cell, and tissue treatments into life-saving medicines. By bringing together deep scientific exper

Dualitas Therapeutics has announced a research collaboration and licence agreement with Roche to discover and develop novel bispecific antibody (BsAb) therapies for immunology and inflammation (I&I) diseases. The DualScreen™ platform is designed to support high-throughput discovery of bispecific antibodies based on proximity biology. Unlike conventional approaches that typically begin with selected target pairs, the platform evaluates a broad range of targets and epitopes